Article Details

Trillium Therapeutics' (NASDAQ:TRIL) Buy Rating Reaffirmed at Cowen

Retrieved on: 2019-09-08 08:56:15

Tags for this article:

Click the tags to see associated articles and topics

Trillium Therapeutics' (NASDAQ:TRIL) Buy Rating Reaffirmed at Cowen. View article details on hiswai:

Excerpt

<div><b>Two Sigma Investments</b> LP bought a new position in shares of Trillium Therapeutics in the 4th quarter valued at about $35,000. Jane Street Group ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo